Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | transitional cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | transitional cell carcinoma | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial (CheckMate 275), Opdivo (nivolumab) treatment in platinum-resistant urothelial carcinoma patients resulted in an objective response rate (ORR) of 20.7% (56/270), a median progression-free survival (mPFS) of 1.9 mo., and a median overall survival (mOS) of 8.6 mo., and patients with CD274 (PD-L1)-positive tumors (IHC>=1% compared to <1%) had improved ORR (25.8%, 32/124 v 16.4%, 24/146), mPFS (3.5 v 1.9 mo), and mOS (11.9 v 6.0 mo) (PMID: 32532789; NCT02387996). | 32532789 |
CD274 positive | transitional cell carcinoma | predicted - sensitive | Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate-274), adjuvant Opdivo (nivolumab) treatment significantly improved the percentage of patients who were alive and disease-free at 6 months (74.5% vs 55.7%, HR 0.55, P<0.001) and median recurrence-free survival (22.9 vs 13.7 mo) compared to placebo in patients with high-risk urothelial carcinoma with a PD-L1 expression level of 1% or more (PMID: 34077643; NCT02632409). | 34077643 |
PubMed Id | Reference Title | Details |
---|---|---|
(32532789) | Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. | Full reference... |
(34077643) | Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. | Full reference... |